Fig. 6: SRC/AR inhibition significantly reduces tumor growth in castrated mice. | Cell Death & Disease

Fig. 6: SRC/AR inhibition significantly reduces tumor growth in castrated mice.

From: N-glycosylation of GDF15 abolishes its inhibitory effect on EGFR in AR inhibitor-resistant prostate cancer cells

Fig. 6

A LT cells were treated with Afatinib (EGFR inhibitor), Bosutinib (SRC inhibitor), and PD98059 (ERK inhibitor) or in combination with EPI or ENZ. B LT cells were treated with siRNAs (si-neg, si-EGFR, si-SRC, and si-ERK1), dominant negative SRC (DNsrc), and overexpression SRC or in combination with EPI or ENZ. Survival rates are shown. Error bars indicate mean ± std of biological triplicates. C Prostate weights in NC and ENZ treatment groups were shown in graph. 5 mice per group. Student’s t-test, *p < 0.05. D GDF15 was immunoprecipitated and then levels of mannose and fucose were quantified with ConA and AAL antibodies. β-tubulin protein was employed as input control. E Prostate weight was showed in graph. n = 5 mice per group. Student’s t-test, *p < 0.05. F Representative images of mouse prostate glands (up panel), prostate lobes (mid panel), and histopathological sections from NC, ENZ, Bosu, and Bosu + ENZ groups. NC negative control, ENZ Enzalutamide treatment, Bosu Bosutinib treatment, Bosu+ENZ, Bosutinib and Enzalutamide combined treatment. Data are expressed as mean ± std. of biological repetitions.

Back to article page